Morning Briefing
Summaries of health policy coverage from major news organizations
Perspectives: Will OPill Be Affordable To Those Who Need It?; Simufilam For Alzheimer's May Be Unsafe
The FDA’s approval of Opill could dramatically improve practical access to family planning. But whether people throughout the country will be able to afford it remains an open question. (Christopher Robertson, J.D., Ph.D., and Anna Braman, B.A., 10/12)
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam. (Adam Feuerstein, 10/17)
The principles underlying the U.S. Supreme Court decision in 303 Creative L.L.C. v. Elenis could have far-reaching implications, possibly affecting our ability to learn about side effects of drugs. (Jerry Avorn, 10/14)
